ArticleTranslational cancer research2026

Residual disease in HER2-positive early breast cancer: are we escalating the RIGHT patients to T-DM1 or T-DXd?

Wiebren Tjalma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.